Navigation Links
Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
Date:3/28/2017

SAN DIEGO, March 28, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference, being held April 3, 2017 at the St. Regis Hotel in New York. 

Details for this presentation are as follows:

  • H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference – webcast available
    Time/Date:  3:20 p.m. ET on Monday, April 3, 2017
    Location:  St. Regis Hotel, New York
    Presentation Room:  Versailles Room

To access the live webcast of Viking's presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for GSD Ia and X-linked adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Follow Viking on Twitter @Viking_VKTX.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-hc-wainwright--cos-1st-annual-nash-investor-conference-300429997.html


'/>"/>
SOURCE Viking Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Viking Therapeutics to Present at the LD Micro Main Event
2. Viking Therapeutics Initiates Phase 2 Trial of VK5211 in Patients Recovering From Hip Fracture
3. Viking Therapeutics to Present at Upcoming Investor Conferences
4. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
5. Leading Alzheimer’s Expert Joins T3D Therapeutics’ Advisory Board
6. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
7. Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
8. FACIT Announces Investment in Propellon Therapeutics
9. Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
10. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
11. eFFECTOR Therapeutics Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC bio, Inc. ... agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC ... retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal diseases. ...
(Date:6/11/2019)... ... June 10, 2019 , ... DeepDyve and ... scientific journals to DeepDyve’s rental service for peer-reviewed journals. , IOPP’s portfolio ... more than 20 million articles, sourced from more than 15,000 journals. , “By ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the ... forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent ... T cells with engineered T cell receptors known as “CARs”. The CAR enables the ...
(Date:5/22/2019)... ... ... Artemis (formerly Agrilyst), the leading enterprise Cultivation Management Platform (CMP), today ... Astanor Ventures and Talis Capital with participation from existing investors New ... company has raised $11.75m to date and will use the new funding to rapidly ...
Breaking Biology Technology:
(Date:6/25/2019)... ... June 25, 2019 , ... ActX ... raw data, easily available from 23andMe, customers can get access to professionally reviewed ... available for both 23andMe Ancestry and Health + Ancestry customers., With the ActX ...
(Date:6/18/2019)... ... June 18, 2019 , ... ... cloud solutions, today introduced Data Science Workstations-as-a-Service as part of its dedicated, multi-GPU, ... BOXX Technologies, Cirrascale Data Science Workstations feature NVIDIA® Quadro RTX™ GPUs for up ...
(Date:6/13/2019)... ... ... KICVentures announced today its plans to host an event at Becker’s 17th ... Chicago on Thursday, June 13th at 6:30 pm. The event will take place at ... Ticino Hospitality room in space #74T. , The event will feature three brief talks ...
Breaking Biology News(10 mins):